RXR activating molecules

Details RXR activating molecules RXR activating molecules

2007-09-04

2007-09-04

Saeed, Kamal A. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S183000

Reexamination Certificate

active

10098184

ABSTRACT:
The invention relates to molecules having Formula (100):wherein ————— represents a bond present or absent; Ar is a substituted or unsubstituted benzene or pyridine ring; V is a C or N atom, and W, X, Y and Z together form a 2,4-thiazolidinedione, 2-thioxo-4-thiazolidinedione, isoxazolidinedione, 2,4-imidazolidinedione, [1,2,4]-oxadiazolidine-3,5-dione or 2-thioxo-4-imidazolidinedione residue; or a pharmaceutically acceptable salt thereof.

REFERENCES:
patent: 4051842 (1977-10-01), Hazel et al.
patent: 4140122 (1979-02-01), Kühl et al.
patent: 4383529 (1983-05-01), Webster
patent: 4668506 (1987-05-01), Bawa
patent: 4713244 (1987-12-01), Bawa et al.
patent: 4788063 (1988-11-01), Fisher et al.
patent: 4824833 (1989-04-01), Iijima et al.
patent: 4897393 (1990-01-01), Iijima et al.
patent: 4931279 (1990-06-01), Bawa et al.
patent: 4948900 (1990-08-01), Iijima et al.
patent: 4971996 (1990-11-01), Shiraishi et al.
patent: 5223522 (1993-06-01), Clark et al.
patent: 5330998 (1994-07-01), Clark et al.
patent: 5512689 (1996-04-01), Quallich
patent: 5523314 (1996-06-01), Bue-Valleskey et al.
patent: 5565324 (1996-10-01), Still et al.
patent: 5650444 (1997-07-01), Cagiano et al.
patent: 5691376 (1997-11-01), Cagiano et al.
patent: 5780676 (1998-07-01), Boehm et al.
patent: 6060596 (2000-05-01), Lerner et al.
patent: 6087103 (2000-07-01), Burmer
patent: 6127415 (2000-10-01), Pfahl et al.
patent: 6168913 (2001-01-01), Hochlowski et al.
patent: 6262044 (2001-07-01), Møller et al.
patent: 6765013 (2004-07-01), Pfahl et al.
patent: 6927228 (2005-08-01), Bernardon et al.
patent: 2002/0143182 (2002-10-01), Pfahl et al.
patent: 2003/0083357 (2003-05-01), Pfahl et al.
patent: 2003/0105333 (2003-06-01), Pfahl et al.
patent: 2003/0144329 (2003-07-01), Pfahl et al.
patent: 2003/0153606 (2003-08-01), Pfahl et al.
patent: 2003/0216432 (2003-11-01), Pfahl et al.
patent: 2004/0034004 (2004-02-01), Pfahl et al.
patent: 2004/0097566 (2004-05-01), Pfahl et al.
patent: 2005/0014767 (2005-01-01), Pfahl et al.
patent: 2005/0038098 (2005-02-01), Tachdjian et al.
patent: 2005/0070581 (2005-03-01), Pfahl et al.
patent: 0 212 617 (1987-03-01), None
patent: 0 304 493 (1989-03-01), None
patent: 0 3343 643 (1989-11-01), None
patent: 1 048 659 (2000-11-01), None
patent: 1 142 885 (2001-10-01), None
patent: 55 038359 (1980-03-01), None
patent: WO 93/21146 (1993-10-01), None
patent: WO 94/12880 (1994-06-01), None
patent: WO 97/00249 (1997-01-01), None
patent: 97/00249 (1997-01-01), None
patent: WO 97/03682 (1997-02-01), None
patent: WO 97/27191 (1997-07-01), None
patent: WO 99/09965 (1999-03-01), None
patent: WO 99/24415 (1999-05-01), None
patent: 99/58127 (1999-11-01), None
patent: WO 99/58127 (1999-11-01), None
patent: 00/10573 (2000-03-01), None
patent: WO 00/18748 (2000-04-01), None
patent: WO 00/32598 (2000-06-01), None
patent: WO 02/071827 (2000-09-01), None
patent: 00/63196 (2000-10-01), None
patent: WO 00 66167 (2000-11-01), None
patent: WO 01/16122 (2001-03-01), None
patent: WO 01/16123 (2001-03-01), None
patent: WO 01/36402 (2001-05-01), None
patent: 02/12210 (2002-02-01), None
patent: WO 02/072009 (2002-09-01), None
patent: WO 02/072543 (2002-09-01), None
patent: 02/080935 (2002-10-01), None
Alley et al., “Feasibility of Drug Screening with Panels of Human Tumor Cell Lines Using a Microculture Tetrazolium Assay,” Cancer Res. 48:589-601 (1988).
Amin et al., “Nitric Oxide Synthase and Cyclooxygenases: Distribution, Regulation, and Intervention in Arthritis,” Nitric Pin. Rheumatol. 11(3):202-209 (1999).
Aranyos et al., “Novel Electron-Rich Bulky Phosphine Ligands Facilitate the Palladium-Catalyzed Preparation of Diaryl Ethers,” J. Am. Chem. Soc. 121:4369-4378 (1999).
Armstrong et al., “Microchip Encoded Combinatorial Libraries: Generation of a Spatially Encoded Library from a Pool Synthesis,”Medicinal Chemistry50(6):258-260 (1996).
Askew et al., “Molecular Recognition with Convergent Function Groups. 6. Synthetic and Structural Studies with a Model Receptor for Nucleic Acid Components,”J. Am. Chem. Soc.111:1082-1090 (1989).
Baldwin et al., “Synthesis of a Small Molecule Combinatorial Library Encoded with Molecular Tags,”J. Am. Chem. Soc.117:5588-5589 (1995).
Baraldi et al., “Exhaled Nitric Oxide Concentrations During Treatment of Wheezing Exacerbation in Infants and Young Children,” Am. J. Respis. Crit. Care Med. 159(4 Pt. 1):1284-1288 (1999).
Beilstein Registry No. 29-30, 1975, Compound Registry No. 1120438.
Beilstien Registry No. 52, 1978, Compound Registry No. 4939128.
Black, “Simple Synthesis of 1-Azaadamantan-4-one,”Synthesis829-830 (1981).
Bradisher et al., “Aromatic Cyclodehydration XXIV. Cyclization of Derivatives of (2-biphenylly)pyruvic Acid,”J. Org. Chem.15(2):374-376 (1950).
Brand and Perrimon, “Target gene expression as a means of altering cell fates and generating dominant phenotypes,”Development118:401-415 (1993).
Bredt et al., “Isolation of Nitric Oxide Synthetase, a Calmodulin-Requiring Enzyme,”Proc. Natl. Acad. Sci.87:682-685 (1990).
Brennan et al., “Inhibitory Effect of TNFα Antibodies on Synovial Cell Interleukin-1 Production in Rheumatiod Arthritis,”Lancet2:244-247 (1989).
Brenner et al., “Encoded Combinatorial Chemistry,”Proc. Natl. Acad. Sci. USA89:5381-5383 (1992).
Chan et al., “New N-and O-Arylations with Phenloboronic Acids and Curpric Acetate,”Tetra. Lett.39:2933-2936 (1998).
Charpentier et al., “Synthesis, Structure—Affinity Relationships, and Biological Activities of Ligands Binding to Retinoic Acid Receptor Subtypes,”J. Med. Chem.38:4993-5006 (1995).
Choi et al., “Similarity of Colorectal Cancer in Crohn's Disease and Ulcerative Colitis: Implications foe Carcinogenesis and Prevention,”Gut35:950-954 (1994).
Cobb et al., “N-(2-Benzolphenyl)-L-tyrosine PPAR Agonists. 3. Structure-Activity Relationship and Optimization of the N-Aryl Substituent,”J. Med. Chem.41:5055-5069 (1998).
Connolly, “Solvent-Accessible Surfaces of Proteins and Nucleic Acids,”Science221:709 (1983).
Darses et al., “Palladium-Catalyzed Cross-Coupling Reactions of Arenediazonium TetraFluoroborates with Aryl- and Alkenylboronic Acids,”Bull. Soc. Chem. Fr.133:1095-1102 (1996).
Ebisawa et al., “Novel Thiazolidinedione Derivatives with Retiniod Synergistic Activity,”Biol. Pharma. Bull.21(5):547-549 (1998).
Egea et al., “Crystal structure of the human RXRα ligand-binding domain bound to its natural ligand:9-cis retinoic acid,”EMBO J.19(11):2592-2601 (2000).
Evans et al., “Synthesis of Diaryl Ethers through the Copper-Promoted Arylation of Phenols with Arylboronic Acids. An Expedient Synthesis of Thyroxine,”Tetra. Lett.39:2937-2940 (1998).
Farahat et al., “Cytokine Expression in Synovial Membranes of Patients with Rheumatiod Arthritis and Osteoarthritis,”Ann. Rheum. Dis.52:870-875 (1993).
Ferrell, “Tripping the Switch Fantastic: How A Protein Kinase Casade Can Convert Graded Inputs in Switch-Like Outputs,”TIBS21:460-466 (1996).
Firooznia et al., “Enantioselective Synthesis of 4-Substituted Phenylalanines By Cross-Couples Reaction,”Tetra. Lett.40:213-216 (1999).
Förstermann et al., “Induced RAW 264.7 Macrophages Express Soluble and Particulate Nitric Oxide Synthase: Inhibition By Transforming Growth Factor-β,”Eur. J. Pharm.225:161-165 (1992).
Fukuto et al., “Inhibition Constitutive and Inducible Nitric Oxide Synthase: Potential Selective Inhibition,”Ann. Rev. Pharmacol. Oxicol.35:1665-194 (1995).
Gahtan et al., “Inflammatory Pathogenesis in Alheimer's Disease: Biological Mechanisms and Cognitive Sequeli,”Neurosci. Biobehav.23:615-633 (1999).
Glauser et al., “Pathogenesis and Potential Strategies for Prevention and Treatment of Septic Shock: An Update,”Cl

Affiliated with

Also associated with

Rating

RXR activating molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with RXR activating molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RXR activating molecules will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3793977